Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Its mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers. All of Merrimack's development programs, including four clinical studies in distinct indications and six candidates in preclinical development, fit into its strategy of 1) understanding the biological problems it is trying to solve, 2) designing specific solutions and 3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to ensure optimal patient outcomes.
Copyright Nasdaq. Minimum 15 minutes delayed.
November 8, 2017 from 8:30 AM to 8:30 AM EST
September 7, 2017 at 12:15 PM EDT
Robert W. Baird 2017 Global Healthcare Conference
April 1 - April 5, 2017 at 12:00 AM EDT
2017 American Association for Cancer Research (AACR) Annual Meeting, April 1-5, 2017
- November 8, 2017